TRLPF Stock UPDATES Trimel Pharmaceutica (TRLPF) 0.4240 09/02/2014
Post# of 273333
Posted On: 09/03/2014 12:50:35 AM
Trimel Pharmaceutica (TRLPF) 0.4240 $TRLPF
First Generation Capital Inc. Converts a Portion of Previously Issued Convertible Note of Trimel Pharmaceuticals Corporation
Marketwire - Fri Aug 22, 5:28PM CDT
Mr. Ian Ihnatowycz announced that effective today, he has converted US$5,151,768.08 aggregate amount (of which US$55,002.59 was accrued interest) of obligations owing under the convertible note (the "Note"
of Trimel Pharmaceuticals Corporation (the "Issuer" that was issued to First Generation Capital Inc. on July 16, 2014 (and amended on July 28, 2014) into 8,945,796 common shares of the Issuer. In accordance with the terms and conditions of the Note, the conversion price was the U.S. dollar equivalent of Cdn.$0.62 per common share, calculated using the Bank of Canada noon rate of exchange on July 15, 2014 (being a conversion price equal to US$0.5759 per common share).
Trimel Announces New TriVair(TM) Website
Marketwire - Thu Jul 31, 4:06PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) announced today that the Company has launched a new website for its dry powder inhalation drug delivery platform TriVair(TM). Winner of the 2009 European Drug Delivery Product Differentiation Innovation of the Year Award, TriVair(TM) is Trimel's novel unit-dose dry powder inhaler / nasal dispersion device. Trimel is interested in establishing partnership arrangements with developers who are looking for a patented, novel dry powder nasal and pulmonary delivery system. For more information, please visit www.trivairdevice.com.
Trimel Provides Corporate Update and Second Quarter 2014 Financial Results
Marketwire - Wed Jul 30, 5:04PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) today provided an overview of its corporate accomplishments and reported financial results for the three month period ended June 30, 2014.
First Generation Capital Inc. Amends Previously Issued Convertible Note of Trimel Pharmaceuticals Corporation
Marketwire - Wed Jul 30, 1:56PM CDT
Mr. Ian Ihnatowycz, announced that effective today, he has entered into an amending agreement (the "Amending Agreement" to the US$25 million convertible note (the "Note" of Trimel Pharmaceuticals Corporation (the "Issuer" issued on July 16, 2014 to his private investment holding company First Generation Capital Inc. (the "Offeror" .
Trimel to Provide Corporate Update and Report Second Quarter 2014 Results
Marketwire - Fri Jul 18, 7:01AM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) will report its second quarter financial results for the period ended June 30, 2014 on July 30, 2014 after market close.
First Generation Capital Inc. Acquires Convertible Note of Trimel Pharmaceuticals Corporation
Marketwire - Thu Jul 17, 1:20PM CDT
Mr. Ian Ihnatowycz announced today that he has acquired a US$25 million convertible note (the "Note" of Trimel Pharmaceuticals Corporation (the "Issuer" through his private investment holding company First Generation Capital Inc. (the "Offeror" . The Note, which pays interest at 9.5% plus the greater of: (a) LIBOR; and (b) 1.0%, and has an initial maturity date of July 16, 2015, is convertible into common shares of the Issuer, in whole or in part at any time after August 21, 2014, at a conversion price, subject to standard anti-dilution adjustments, of the US dollar equivalent of $0.62 (calculated using the July 15, 2014 Bank of Canada noon buying rate for US dollars of US$1 equals $1.0766). The purchase was made on a private placement basis from the Issuer.
IIROC Trade Resumption - Trimel Pharmaceuticals Corporation
Newsfile Corp - Thu Jul 17, 12:51PM CDT
Trading resumes in:
IIROC Trade Halt - Trimel Pharmaceuticals Corporation
Newsfile Corp - Thu Jul 17, 12:50PM CDT
The following issues have been halted by IIROC:
Should Trimel Pharmaceuticals (TRLPF) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 7:49AM CDT
Trimel Pharmaceuticals (TRLPF)has been overlooked by investors but it has actually seen estimates rise over the past month.
Trimel to Present at the JMP Securities Healthcare Conference
Marketwire - Wed Jun 18, 2:00PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that management is scheduled to present an overview of the Company at the JMP Securities Healthcare Conference at the Westin New York Grand Central, New York on June 24, 2014 at 12:00 p.m. (Eastern time). The presentation materials will also be made available on the Trimel website at www.trimelpharmaceuticals.com.
Trimel to Present at the 2014 Bloom Burton & Co. Healthcare Investor Conference
Marketwire - Wed Jun 18, 1:21AM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that management is scheduled to present an overview of the Company at the 2014 Bloom Burton & Co. Healthcare Investor Conference at the Toronto Board of Trade on June 18th, 2014 at 2:30 p.m. (Eastern time). The presentation materials will also be made available on the Trimel website at www.trimelpharmaceuticals.com.
Trimel Reports Additional Results From Tefina(TM) Phase II Clinical Trial
Marketwire - Mon Jun 16, 5:01AM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) reported results from further analysis of its Phase II clinical trial evaluating the efficacy and safety of Tefina(TM), a "use-as-required" testosterone nasal gel for the treatment of Female Orgasmic Disorder (FOD).
First Generation Capital Inc. Converts a Portion of Previously Issued Convertible Note of Trimel Pharmaceuticals Corporation
Marketwire - Fri Aug 22, 5:28PM CDT
Mr. Ian Ihnatowycz announced that effective today, he has converted US$5,151,768.08 aggregate amount (of which US$55,002.59 was accrued interest) of obligations owing under the convertible note (the "Note"
of Trimel Pharmaceuticals Corporation (the "Issuer" that was issued to First Generation Capital Inc. on July 16, 2014 (and amended on July 28, 2014) into 8,945,796 common shares of the Issuer. In accordance with the terms and conditions of the Note, the conversion price was the U.S. dollar equivalent of Cdn.$0.62 per common share, calculated using the Bank of Canada noon rate of exchange on July 15, 2014 (being a conversion price equal to US$0.5759 per common share). Trimel Announces New TriVair(TM) Website
Marketwire - Thu Jul 31, 4:06PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) announced today that the Company has launched a new website for its dry powder inhalation drug delivery platform TriVair(TM). Winner of the 2009 European Drug Delivery Product Differentiation Innovation of the Year Award, TriVair(TM) is Trimel's novel unit-dose dry powder inhaler / nasal dispersion device. Trimel is interested in establishing partnership arrangements with developers who are looking for a patented, novel dry powder nasal and pulmonary delivery system. For more information, please visit www.trivairdevice.com.
Trimel Provides Corporate Update and Second Quarter 2014 Financial Results
Marketwire - Wed Jul 30, 5:04PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) today provided an overview of its corporate accomplishments and reported financial results for the three month period ended June 30, 2014.
First Generation Capital Inc. Amends Previously Issued Convertible Note of Trimel Pharmaceuticals Corporation
Marketwire - Wed Jul 30, 1:56PM CDT
Mr. Ian Ihnatowycz, announced that effective today, he has entered into an amending agreement (the "Amending Agreement"
to the US$25 million convertible note (the "Note" of Trimel Pharmaceuticals Corporation (the "Issuer" issued on July 16, 2014 to his private investment holding company First Generation Capital Inc. (the "Offeror" . Trimel to Provide Corporate Update and Report Second Quarter 2014 Results
Marketwire - Fri Jul 18, 7:01AM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) will report its second quarter financial results for the period ended June 30, 2014 on July 30, 2014 after market close.
First Generation Capital Inc. Acquires Convertible Note of Trimel Pharmaceuticals Corporation
Marketwire - Thu Jul 17, 1:20PM CDT
Mr. Ian Ihnatowycz announced today that he has acquired a US$25 million convertible note (the "Note"
of Trimel Pharmaceuticals Corporation (the "Issuer" through his private investment holding company First Generation Capital Inc. (the "Offeror" . The Note, which pays interest at 9.5% plus the greater of: (a) LIBOR; and (b) 1.0%, and has an initial maturity date of July 16, 2015, is convertible into common shares of the Issuer, in whole or in part at any time after August 21, 2014, at a conversion price, subject to standard anti-dilution adjustments, of the US dollar equivalent of $0.62 (calculated using the July 15, 2014 Bank of Canada noon buying rate for US dollars of US$1 equals $1.0766). The purchase was made on a private placement basis from the Issuer. IIROC Trade Resumption - Trimel Pharmaceuticals Corporation
Newsfile Corp - Thu Jul 17, 12:51PM CDT
Trading resumes in:
IIROC Trade Halt - Trimel Pharmaceuticals Corporation
Newsfile Corp - Thu Jul 17, 12:50PM CDT
The following issues have been halted by IIROC:
Should Trimel Pharmaceuticals (TRLPF) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 7:49AM CDT
Trimel Pharmaceuticals (TRLPF)has been overlooked by investors but it has actually seen estimates rise over the past month.
Trimel to Present at the JMP Securities Healthcare Conference
Marketwire - Wed Jun 18, 2:00PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that management is scheduled to present an overview of the Company at the JMP Securities Healthcare Conference at the Westin New York Grand Central, New York on June 24, 2014 at 12:00 p.m. (Eastern time). The presentation materials will also be made available on the Trimel website at www.trimelpharmaceuticals.com.
Trimel to Present at the 2014 Bloom Burton & Co. Healthcare Investor Conference
Marketwire - Wed Jun 18, 1:21AM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that management is scheduled to present an overview of the Company at the 2014 Bloom Burton & Co. Healthcare Investor Conference at the Toronto Board of Trade on June 18th, 2014 at 2:30 p.m. (Eastern time). The presentation materials will also be made available on the Trimel website at www.trimelpharmaceuticals.com.
Trimel Reports Additional Results From Tefina(TM) Phase II Clinical Trial
Marketwire - Mon Jun 16, 5:01AM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) reported results from further analysis of its Phase II clinical trial evaluating the efficacy and safety of Tefina(TM), a "use-as-required" testosterone nasal gel for the treatment of Female Orgasmic Disorder (FOD).
(0)
(0)